MorphoSys (MOR)

Business description

MorphoSys is a German biotechnology company that uses its proprietary antibody platforms to produce human antibodies for therapeutic use across a range of indications for partners and to develop its own pipeline.

Share price chart

Share chart

Stock data

Market cap.€1776.8m
Last close€67.15
High / Low (52 weeks)€86.8 / €57.2
Stock market listingDE
Forecast net cash (€m)309
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(4.5)(9.1)4.8
Relative *(3.1)(20.1)(15.3)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
Avacta Group AVEO Pharmaceuticals
Avita Medical Balda
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
BTG Can-Fite BioPharma
Capstone Therapeutics Cardio3 BioSciences
Carmat Celldex Therapeutics
Cellectis Cerulean
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel Consort Medical
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Epistem Holdings Erytech Pharma
Esperion Therapeutics Evolva
Evotec Exact Sciences
Exelixis Formycon
Futura Medical Galapagos
Galmed Pharmaceuticals Genfit
Genmab GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunodiagnostic Systems Holdings
ImmuPharma Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene Midatech
MolMed Mologen AG
Momenta Pharmaceuticals Nanobiotix
Nanosonics Nektar Therapeutics
NeoStem Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Ossur OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon Pharmacyclics
Pharmaxis Pharming Group
Photocure Phylogica
Prescient Therapeutics Prima BioMed
ProMetic Life Sciences Prosensa
Proteome Sciences QRxPharma
Quantum Pharmaceuticals Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
Tekmira TESARO
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Tonix Pharmaceuticals
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB UDG Healthcare
uniQure NV Vectura
Verastem Verisante Technology
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
WaferGen Biosystems Wilex
Xencor Zafgen
Zealand Pharma Zeltia
Ziopharm Oncology

Company news

MorphoSys AG Reports Results for Fiscal Year 2014

Thu, 26 Feb 2015 06:10:20 GMT

MorphoSys AG: Announcement of the Convening of the AGM in Munich ...

Mon, 30 Mar 2015 11:48:45 GMT

MorphoSys AG: MorphoSys und Celgene vereinbaren Beendigung der MOR202 ...

Thu, 26 Mar 2015 16:07:30 GMT

Invitation to Year End 2014 Conference Call of MorphoSys AG on 26 February ...

Fri, 20 Feb 2015 10:06:01 GMT

MorphoSys AG : MorphoSys to Receive Milestone Payment for Guselkumab ...

Mon, 13 Apr 2015 05:26:15 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2013A 78.0 18.1 14.0 43.5 154.4 18.2
2014A 64.0 (1.8) (1.6) (1.3) N/A N/A
2015E 104.1 11.9 12.5 37.6 178.6 N/A
2016E 49.7 (43.7) (43.6) (111.8) N/A N/A

Last updated on 20/04/2015

Investment summary

MorphoSys and Celgene have ended their co-development alliance for MOR202. This has no immediate impact on MOR202's development, and initial data from the Phase I/II in multiple myeloma will be reported at ASCO at the end of May. Meanwhile, MorphoSys is planning a head-to-head study with MOR208 against rituximab in diffuse large B-cell lymphoma (DLBCL). The company had a setback with Roche ending one of two trials with gantenerumab in Alzheimer's disease. We value MorphoSys at €1.76bn.

Last updated on 20/04/2015

Industry outlook

The pharmaceutical industry is out-licensing more drug discovery and developing more biological products, both trends that should benefit MorphoSys. Also, there is increasing demand for novel therapies, such as those in MorphoSys's proprietary pipeline.

Last updated on 31/03/2015

Key management

Gerald Moller, Chairman
Simon E. Moroney, CEO
Jens Holstein, CFO

Company address

Lena-Christ-Str. 48
82152 Martinsried/Planegg
Germany
+49 (0)89 / 899 27-0
View website